Loading clinical trials...

Imaging Characteristics of Different ⁶⁸Ga-PSMA Probes in Prostate Cancer | Clinical Trials | Clareo Health

NOT_YET_RECRUITINGNA

Imaging Characteristics of Different ⁶⁸Ga-PSMA Probes in Prostate Cancer

Comparative Study on Imaging Characteristics of Different ⁶⁸Ga-Labeled PSMA Probes in Patients With Prostate Cancer

NCT07365397•Shanghai Zhongshan Hospital

Summary

This study aims to evaluate the imaging characteristics of \[⁶⁸Ga\]Ga-GS24-B2-250-T Injection (abbreviated as ⁶⁸Ga-GS24-B2-250-T), \[⁶⁸Ga\]Ga-GS24-B2-268-T Injection (abbreviated as ⁶⁸Ga-GS24-B2-268-T), \[⁶⁸Ga\]Ga-GS24-B2-237-T Injection (abbreviated as ⁶⁸Ga-GS24-B2-237-T), and \[⁶⁸Ga\]Ga-PSMA-11 Injection (abbreviated as ⁶⁸Ga-PSMA-11) as PET/CT imaging agents in patients with prostate cancer.

Eligibility

Age

18 - No limit years

Sex

MALE

Healthy Volunteers

Inclusion Criteria

•1. The subject has fully understood the trial content, process, and potential risks, and has voluntarily signed the informed consent form;
•2. Male subjects aged ≥ 18 years;
•3. Clinically or radiologically assessed as metastatic hormone-sensitive prostate cancer (mHSPC) or metastatic castration-resistant prostate cancer (mCRPC);
•4. Eastern Cooperative Oncology Group (ECOG) performance status score of 0-2;
•5. Presence of positive lesions on ⁶⁸Ga-PSMA-11 PET/CT scan;
•6. Blood routine, renal function, and liver function tests meeting the following criteria:
•1. Platelet count \> 90 × 10⁹/L;
•2. Urea/urea nitrogen and serum creatinine \< 1.5 × upper limit of normal (ULN);
•3. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) \< 2.5 × ULN;
•7. Expected survival time ≥ 6 months;
+1 more criteria

Exclusion Criteria

•1. Having participated in another interventional clinical trial prior to signing the informed consent form and being within 5 half-lives of the investigational product of that trial; or currently participating in another interventional clinical trial; or having participated in a clinical trial involving radiopharmaceuticals prior to signing the informed consent form with an interval of less than 3 months between the last dose and the informed consent signing date.
•2. Having received any intravenous iodine-containing contrast agent within 24 hours prior to administration, or any high-density oral contrast agent (e.g., barium sulfate) within 5 days prior to administration. Oral water-soluble contrast agents (e.g., compound meglumine diatrizoate oral solution) are acceptable.
•3. Having received high-energy γ-ray-emitting agents (\>300 KeV, e.g., radiopharmaceuticals labeled with radionuclides such as \[¹³¹I\]I, \[¹⁸F\]F, \[⁶⁸Ga\]Ga, \[⁶⁴Cu\]Cu, etc.) within a period equivalent to either 5 half-lives of the agent or 2 days, whichever is longer, prior to administration.
•4. Planning to adjust anti-tumor medication during the study period.
•5. Being unable to complete the required PET/CT imaging procedures.
•6. Having any medical condition or other circumstances that, in the investigator's judgment, may affect the safety or compliance of the subject.

Key Dates

Start Date

January 19, 2026

Primary Completion Date

June 14, 2026

Completion Date

July 26, 2026

Last Updated

January 26, 2026

Enrollment

ESTIMATED participants

Conditions

Prostate Cancer

Interventions

68Ga-GS24-B2-268-T

DIAGNOSTIC_TEST

68Ga-GS24-B2-250-T

DIAGNOSTIC_TEST

68Ga-GS24-B2-237-T

DIAGNOSTIC_TEST

68Ga-PSMA-11

DIAGNOSTIC_TEST

A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

NCT06842498

Metastatic Castration-Resistant Prostate Cancer

View study

RECRUITINGPHASE2

Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells

NCT05691465

Metastatic Prostate Adenocarcinoma With Neuroendocrine DifferentiationMetastatic Prostate Neuroendocrine Carcinoma+2 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: January 26, 2026Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Imaging Characteristics of Different ⁶⁸Ga-PSMA Probes in Prostate Cancer

Inclusion Criteria

Exclusion Criteria

A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells

Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations

Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)

PSMA-PET: Deep Radiomic Biomarkers of Progression and Response Prediction in Prostate Cancer

Phase 2a Study of High-Dose Testosterone Followed by Radioligand Therapy in mCRPC